article Open AccessTop 1% cited

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

Clinical Cancer Research · 2013 · Vol. 20(3) · pp. 764–775

Kathryn P. Pennington(Medical Genetics Center)Tom Walsh(University of Washington Medical Center)Maria I. Harrell(Medical Genetics Center)Ming K. Lee(University of Washington Medical Center)Christopher C. Pennil(Medical Genetics Center)Mara H. Rendi(Medical Genetics Center)Anne Thornton(Medical Genetics Center)Barbara M. Norquist(University of Washington Medical Center)Silvia Casadei(University of Washington Medical Center)Alex S. Nord(Medical Genetics Center)Kathy Agnew(Medical Genetics Center)Colin C. Pritchard(University of Washington Medical Center)Sheena Scroggins(Medical Genetics Center)Rochelle L. Garcia(University of Washington Medical Center)Mary‐Claire King(University of Washington Medical Center)Elizabeth M. Swisher✉(University of Washington Medical Center)

View via DOI Publisher page

Abstract

Germline or somatic mutations in homologous recombination genes are present in almost one third of ovarian carcinomas, including both serous and nonserous histologies. Somatic BRCA1/2 mutations and mutations in other homologous recombination genes have a similar positive impact on overall survival and platinum responsiveness as germline BRCA1/2 mutations. The similar rate of homologous recombination mutations in nonserous carcinomas supports their inclusion in PARP inhibitor clinical trials.

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy BRCA gene mutations in cancerHomologous recombinationGermline mutationGermlineBiologySomatic cellNon-allelic homologous recombinationHomologous chromosomeGeneticsCancer researchBRCA2 Protein

MeSH terms

AdultAgedAged, 80 and overAntineoplastic AgentsCarcinomaFallopian Tube NeoplasmsFemaleHumansMiddle AgedMutationOvarian NeoplasmsPeritoneal NeoplasmsGene Expression Regulation, NeoplasticPlatinum CompoundsDrug Resistance, Neoplasm

Citations

1,038

FWCI

63.11

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Epithelial ovarian cancer: Evolution of management in the era of precision medicine